Last update 21 Nov 2024

DXC-007

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Target
CD33 x Tubulin
Mechanism
CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors), Tubulin inhibitors
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication
Refractory acute myeloid leukemiaRelapsing acute myeloid leukemia
Inactive Indication-
Originator Organization
Hangzhou DAC Biotechnology Co., Ltd.Hangzhou DAC Biotechnology Co., Ltd.
Active Organization
Hangzhou DAC Biotechnology Co., Ltd.Hangzhou DAC Biotechnology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC7H13NO3S
InChIKeyGDDITXNHVSEICM-YFKPBYRVSA-N
CAS Registry-
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

1
Clinical Trials associated with DXC-007
CTR20221074 / RecruitingPhase 1
评估注射用DXC007（重组人源化抗CD33单抗-Tub255偶联剂）在复发/难治性急性髓系白血病患者中的安全性、耐受性、药代动力学特征的开放、多中心、首次人体、剂量递增和扩大入组的I期临床研究
[Translation] An open, multicenter, first-in-human, dose-escalation and expansion phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of DXC007 (recombinant humanized anti-CD33 monoclonal antibody-Tub255 conjugate) for injection in patients with relapsed/refractory acute myeloid leukemia
100 Clinical Results associated with DXC-007
Login to view more data
100 Translational Medicine associated with DXC-007
Login to view more data
100 Patents (Medical) associated with DXC-007
Login to view more data
100 Deals associated with DXC-007
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 1
CN
Hangzhou DAC Biotechnology Co., Ltd.Hangzhou DAC Biotechnology Co., Ltd.
30 Jun 2022
Relapsing acute myeloid leukemiaPhase 1
CN
Hangzhou DAC Biotechnology Co., Ltd.Hangzhou DAC Biotechnology Co., Ltd.
30 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free